The thesis

Royalty Pharma operates as a buyer of biopharmaceutical royalties with a portfolio of 35 marketed therapies. The company's revenue growth is 16.5% YoY. Its net margin is 3215.0%, indicating high profitability. The conviction score is 28/100, suggesting a medium level of conviction.

Why now

The current macro context of increased sanctions and geopolitical tensions may impact the biopharmaceutical industry, making Royalty Pharma's diversified royalty portfolio more attractive. The company's strong revenue growth and high margins make it an interesting setup in this environment.

What to watch

The company's revenue growth and net margin over the next quarter will indicate whether its current trajectory is sustainable. The progress of its development-stage product candidates will also be a key indicator of future growth potential.

Key risks

Valuation risk is high given the P/E ratio of 34.9x. Execution risk is present as the company's growth depends on the success of its portfolio therapies and development-stage product candidates. Macro risk is significant due to the potential impact of geopolitical tensions and sanctions on the biopharmaceutical industry.

Theme exposure